Related by context. All words. (Click for frequent words.) 72 randomized Phase III 72 BRIM3 71 phase IIb clinical 71 multicenter Phase II 71 Phase IIB 71 NO# [002] 71 Phase Ib II 71 BRIM2 70 PRIMO CABG2 70 ADVANCE PD 70 Phase 1a clinical 70 pivotal bioequivalence 70 phase IIa 69 phase Ib 69 placebo controlled clinical 69 phase IIb 69 alvespimycin 69 phase IIa clinical 69 ToGA 69 Phase Ib clinical 69 CA9 SCAN 69 tolevamer 69 oral ridaforolimus 68 EchoCRT 68 randomized controlled multicenter 68 ongoing Phase IIIb 68 MAGE A3 ASCI 68 multicenter Phase III 68 Phase IIb III 68 thorough QT 68 APEX PD 68 RE LY ® 68 Phase #b/#a clinical 68 ONTARGET 68 blinded randomized placebo controlled 68 Phase IIIb clinical 67 Zemplar Capsules 67 multicenter trials 67 placebo controlled Phase III 67 PRIMO CABG 67 placebo controlled multicenter 67 PANVAC VF 67 teriflunomide 67 double blinded randomized 67 STRIDE PD 67 ENDEAVOR IV 67 XL# SAR# 67 MIST II 67 BCIRG 67 EMPOWER ™ 67 CHAMPION PCI 67 HGS# 67 PSMA ADC 67 phase IIb study 67 PEARL SC 66 reslizumab 66 phase IIIb 66 mg/m2 cohort 66 Prostate AdenoCarcinoma Treatment 66 forodesine 66 DASISION 66 CARE HF 66 BrachySil TM 66 multicenter Phase 66 registrational Phase 66 BioMarck 66 ASCEND HF 66 MADIT II 66 PFO migraine 66 UPLYSO 66 prospective randomized controlled 66 PCI ExTRACT TIMI 66 riociguat 66 ThermoDox ® clinical 66 randomized Phase 2b 66 NeuroFlo 66 VITAL Trial 66 maximally tolerated dose 66 GetGoal Phase III 66 prospective multicentre 66 Proellex TM 66 lomitapide 66 TLK# 66 pharmacokinetic PK 66 JAK inhibitor 66 tramiprosate Alzhemed TM 66 trastuzumab emtansine T DM1 66 PREVENT IV 66 rALLy clinical trial 66 Allovectin 7 R 65 phase IIb trial 65 ADMIRE HF 65 Phase #b/#a 65 Phase Ib IIa 65 double blinded placebo 65 Phase 1b clinical 65 ENDEAVOR III 65 ACTEMRA TM 65 randomized Phase IIb 65 AVADO 65 Bayer HealthCare Onyx Pharmaceuticals 65 ZOLINZA 65 SUCCEED trial 65 treatment naive genotype 65 MEND CABG II 65 Phase IIa trials 65 neratinib 65 ACCORD Lipid 65 Multicenter Automatic Defibrillator Implantation 65 placebo controlled Phase 65 Phase #/#a clinical 65 elotuzumab 65 multicenter randomized controlled 65 successfully commercialize Iluvien 65 deforolimus 65 multicenter randomized placebo controlled 65 CRMD# 65 GAMMAGARD 65 ACCEDE 65 Allovectin 7 ® 65 PRESEPT 65 Phase IIIb 65 CURE AF 65 PERSEUS 65 DSMB recommended 65 NATRECOR ® 65 Stedivaze 65 multicentre randomized 65 AIM HIGH 65 Phase 2b study 65 Long Lesion 65 vidofludimus 65 Phase IIb clinical trials 65 EmbraceAC 65 PRADAXA 65 subcutaneous PRO 65 Tarceva TM 65 evaluating Actimmune 65 pharmacodynamic effects 65 ExTRACT TIMI 65 ZYBRESTAT fosbretabulin 65 mertansine 65 relapsed MM 65 MYTHOS trial 65 ANCHOR trial 65 Vectibix panitumumab 65 acyclovir Lauriad R 65 CIMZIA ™ 65 ENESTnd 65 multicenter clinical 65 bevirimat Study 65 Phase IIb clinical 65 EDEMA3 65 MERLIN TIMI 65 trastuzumab DM1 T DM1 65 ENGAGE AF TIMI 65 LUX Lung 65 Thorough QT 65 MEND CABG 65 opioid induced bowel dysfunction 64 ONCONASE R 64 Azedra 64 visilizumab 64 Anturol TM 64 REMINYL ® 64 cathepsin K inhibitor 64 bicifadine 64 Phase 2a trial 64 Randomized controlled 64 evaluating tivozanib 64 initiate multicenter 64 Phase 1b trial 64 placebo controlled randomized 64 Clinical Antipsychotic Trials 64 ongoing Phase 1b 64 dose escalation Phase 64 dosing cohort 64 Phase III VISTA 64 oral rivaroxaban 64 Vitaxin 64 Novo TTF 64 MGd 64 ALSYMPCA 64 DU #b 64 Empatic ™ 64 blinded randomized controlled 64 Cloretazine 64 evaluating mipomersen 64 RSD# oral 64 randomized blinded 64 pharmacodynamic properties 64 bardoxolone 64 Phase #/#a 64 phase 2a 64 number NCT# ClinicalTrials.gov 64 TASKi3 64 nonrandomized 64 ROCKET AF 64 enzastaurin 64 Solazed 64 ORAL Solo 64 Arikace 64 Phase III placebo controlled 64 HGS ETR2 64 HuMax EGFr 64 randomized controlled Phase 64 R#/MEM # 64 AZOR 64 fidaxomicin Phase 64 ABSORB trial 64 prospective randomized placebo 64 BETAS 64 confirmatory Phase III 64 NSABP B 64 phase III ACCLAIM 64 RE LY 64 Ophena 64 ponatinib 64 clinical pharmacology studies 64 CIMZIA TM 64 huN# DM1 64 huC# DM4 64 HCV SPRINT 64 OvaRex MAb 64 preclinical efficacy 64 Phase Ib study 64 CALGB # [002] 64 Phase 2a clinical 64 CURRENT OASIS 7 64 Phase IIb trials 64 Phase 2b kidney transplant 64 eprotirome 64 APPRAISE 64 AEGR 64 inhaled AAT 64 Phase Ib 64 midstage clinical 63 multicenter placebo controlled 63 IMPACT DCM clinical 63 ENRICH trial 63 REVIVE Diabetes 63 azilsartan medoxomil 63 Maximum Tolerated Dose MTD 63 AVERROES 63 StemEx 63 Phase 1b clinical trials 63 initiate Phase 1b 63 multicenter multinational 63 Oral NKTR 63 placebo controlled clinical trials 63 randomized multicenter Phase III 63 pharmacodynamic PD 63 Carotid Revascularization Endarterectomy vs. 63 QTinno TM 63 brivaracetam 63 fosbretabulin 63 lintuzumab 63 Dose escalation 63 Ophena TM 63 viral kinetic 63 Asentar 63 Phase Ib clinical trials 63 HCV RESPOND 2 63 SUTENT ® 63 PRE SURGE 63 Dextofisopam 63 landmark ATHENA 63 including eniluracil ADH 63 CLIRS trial 63 European Sepsis Trial 63 Phase III metastatic melanoma 63 Aurora kinase inhibitor 63 IIa clinical 63 CALGB 63 ticagrelor Brilinta 63 budesonide foam 63 PROMUS Element Stent 63 everolimus eluting stents 63 EXPLORE Xa 63 interferon gamma 1b 63 OncoVEX GM CSF 63 cytokine refractory 63 LEUKINE 63 budesonide MMX Phase III 63 ELACYT 63 AERx iDMS 63 Phase lll 63 Orazol 63 Trofex 63 HCD# [002] 63 ARCOXIA 63 phase IIb III 63 Xelox 63 pain palliation 63 TAXUS ATLAS 63 Onrigin 63 prospective multicenter randomized 63 randomized multicenter trial 63 PDE4 inhibitor 63 ENMD # 63 catheter occlusion 63 Panzem R NCD 63 metastatic HRPC 63 Vaxfectin R 63 QLT Plug Delivery 63 Phase 1a 63 BioMatrix TM 63 Phase III randomized controlled 63 LibiGel Phase III 63 axitinib 63 dacetuzumab 63 Plicera 63 SUSTENNA TM 63 Phase IIIb study 63 hypoxia activated prodrug 63 YONDELIS 63 PrevOnco 63 IMA# 63 cangrelor 63 recurrent malignant glioma 63 Kamada AAT 63 XL# XL# XL# XL# 63 prospectively defined 63 pharmacokinetics PK 63 dose cohort 63 balsalazide tablet 63 AVOREN 63 BOLDER II 63 SAR# [004] 63 includes TOLAMBA TM 63 Exherin TM 63 PD LID 63 Cethromycin 63 Zevalin consolidation 63 NP2 Enkephalin 63 Val HeFT 63 Phase 2b clinical 63 AVN# Phase 63 lumiliximab 63 LUMINATE 63 PRECISE Trial 63 galiximab 63 TAXUS IV 63 OvaRex ® MAb 63 DEB# 63 randomized controlled clinical 63 Pivotal Phase III 63 prospective multicenter 63 albiglutide 63 CATIE AD 63 randomized clinical 63 APEX AMI trial 63 Exelixis compounds 63 registrational 62 tremelimumab 62 Initiate Phase 62 phase Ib clinical 62 Prestara 62 MYDICAR 62 CBLC# 62 multicenter phase 62 bazedoxifene conjugated estrogens 62 Perforomist Inhalation Solution 62 clinical endpoints 62 Octreolin 62 HGS ETR1 mapatumumab 62 pharmacodynamic profile 62 dose escalation phase 62 Amoxicillin PULSYS Phase III 62 evaluating satraplatin plus 62 BARI 2D 62 assessing T DM1 62 sargramostim 62 SYMMETRY trial 62 GRAVITAS trial 62 LAB CGRP 62 recombinant PSMA vaccine 62 urocortin 2 62 Phase III multicenter 62 GVAX ® 62 MYDICAR ® 62 CIMZIA TM certolizumab pegol 62 CVac 62 Intervention Effectiveness 62 hoFH 62 PRT# 62 PDX pralatrexate 62 ADAGIO study 62 eribulin mesylate 62 fidaxomicin Phase 3 62 INCB# [001] 62 BLA filing 62 PrandiMet TM 62 eritoran 62 velafermin 62 SPIRIT FIRST 62 candidate CRLX# 62 FOLOTYN ® 62 Xanafide 62 pharmacodynamics PD 62 VADT 62 CLORETAZINE TM VNP#M 62 novel oral anticoagulant 62 CoFactor 62 BLP# Liposome Vaccine 62 Initiated Phase 62 IMPACT DCM 62 SYNERGY Stent 62 OvaRex R 62 CINQUIL 62 blinded randomized 62 SIMPADICO 62 SILENOR 62 AZILECT R 62 active comparator 62 controlled multicenter 62 TEMSO 62 Phase IIA 62 paclitaxel poliglumex 62 registrational trial 62 prospectively stratified 62 cannabinor 62 ACTIVE W 62 cilengitide 62 docetaxel Taxotere R 62 #mg dose [002] 62 Glufosfamide 62 ganetespib 62 tecarfarin 62 lintuzumab SGN 62 rALLy trial 62 Afatinib 62 Aflibercept 62 OncoVex 62 Ixempra 62 Catena ® 62 severe hypercholesterolemia 62 epoetin alpha 62 TransVax TM 62 EOquin TM 62 INTEGRILIN 62 Bezielle 62 SCH # 62 peginesatide 62 TMC# C# 62 Edge STudy 62 Hepatocellular Carcinoma HCC 62 Genz # 62 Multiple Ascending Dose 62 Randomized Double blind 62 OMNARIS Nasal Spray 62 HGS ETR1 62 DEEP AF 62 tubulin inhibitor 62 nab paclitaxel 62 ORENCIA R 62 desvenlafaxine succinate 62 multicenter randomized clinical 62 Insegia 62 SPIRIT IV 62 CAMMS# 62 oral picoplatin 62 TELCYTA 62 ENDEAVOR II 62 reduce serum phosphate 62 zotarolimus 62 recurrent metastatic ovarian cancer 62 PARTNER Trial 62 Phase 1b 62 Pivotal Phase 62 NeuroSTAT ® 62 subgroup analyzes 62 Nasulin 62 bioequivalency 62 ancrod 62 samalizumab 62 APEX AMI 62 TOLAMBA 62 sorafenib Nexavar 62 morphometric vertebral fractures 62 olaparib 62 Cloretazine ® 62 StemEx R 62 optimal dosing regimen 62 NEVO RES 62 PI3K/Akt pathway inhibitor 62 sunitinib malate 62 gefitinib Iressa 62 placebo controlled studies 62 Phase III confirmatory 62 TBC# 62 SCD HeFT 62 multicentre randomized controlled 62 dalbavancin 62 Atrasentan 62 Cervista HPV HR 62 oral prodrug 62 canakinumab 62 SEPET TM 62 TransVax tm 62 Deforolimus 62 vorinostat 62 SPIRIT III 62 Silodosin 62 EFAPROXYN 62 Bicifadine 62 midstage trials 62 Medidur FA 62 BAY #-# 62 pharmacodynamic markers 62 concurrent chemoradiation 62 REALITY Trial 62 PrevOnco ™ 62 NV1FGF 62 Entereg R 61 Androxal TM 61 eTag assays 61 HOPE TOO 61 Vernakalant 61 Phase III clinical 61 Vimpat R 61 PreCISe 61 RELOVAIR ™ 61 ospemifene 61 NSABP 61 randomized discontinuation trial 61 Tesmilifene 61 ATACAND 61 Achieves Primary Endpoint 61 Randomized Evaluation 61 tolerated dose MTD 61 #D#C# 61 CAPACITY trials 61 EVEREST II 61 GEM OS2 61 adecatumumab 61 EMPHASIS HF trial 61 Hedgehog Pathway Inhibitor 61 AZILECT ® 61 trodusquemine 61 Egrifta 61 multicentre prospective 61 DXL# 61 novel histone deacetylase 61 torezolid phosphate 61 formal pharmacokinetic PK 61 EndoTAG TM -1 61 XL# anticancer compounds 61 MADIT 61 lenalidomide Revlimid R 61 Elagolix 61 Randomized Phase 61 CUSTOM III 61 intensive lipid lowering 61 PEG SN# 61 LibiGel ® 61 Poly ICLC 61 Cloretazine R VNP#M 61 ganaxolone 61 adjuvant colon cancer 61 GALNS 61 GLP toxicology studies 61 LungAlert TM 61 COMFORT II 61 ruxolitinib 61 NSABP C 61 randomized discontinuation 61 BLOOM DM 61 pharmacokinetics pharmacodynamics 61 HuLuc# 61 CCR5 mAb 61 solid tumors ZYBRESTAT 61 Augment Injectable 61 Clonicel 61 bosutinib 61 APTIVUS 61 Omacetaxine 61 Allovectin 7 61 FOLFOX6 chemotherapy regimen 61 lesinurad 61 adenosine injection 61 antiangiogenic agent 61 oral deforolimus 61 TriRima 61 Intravail R 61 ISTODAX 61 PRECISE trial 61 Lixivaptan 61 PROMACTA ® 61 NATRECOR R 61 novel VDA molecule 61 PROTEGE 61 GLPG# 61 Curaxin CBLC# 61 Prospective Randomized 61 vivo preclinical 61 AEG# 61 GVAX Pancreas Vaccine 61 Forodesine HCl 61 granted Ortec 61 Dacogen injection 61 evaluating REVLIMID 61 Xcytrin R 61 #I TM# 61 ILLUMINATE 61 Tykerb lapatinib 61 NABTT 61 volociximab 61 partner Lux Biosciences 61 alicaforsen enema 61 CMV vaccine 61 PF # [002] 61 TG MV 61 PROVENGE ® 61 secondary efficacy endpoints 61 ORAL Sync 61 Traficet EN 61 TAXUS TM 61 R# #mg BID 61 Crofelemer budesonide foam 61 AIMM trial 61 ataluren 61 PROSTVAC ® 61 VIRAMUNE XR 61 oral salmon calcitonin 61 Ostarine 61 eltrombopag 61 dose intramuscular 61 COSTAR II 61 Phase 2a clinical trials 61 Meta analyzes 61 Phase #b/#a trial 61 miconazole Lauriad ® 61 Phase Ia 61 brand ciclesonide HFA 61 pexelizumab 61 PRESEPT study 61 randomized multicenter 61 O PPDS 61 AQ4N 61 pharmacokinetic PK study 61 Val MARC 61 Active Ulcerative Colitis 61 Symadex 61 paclitaxel eluting stent 61 Myocet 61 PSN# [002] 61 dexanabinol 61 induced macular edema 61 refractory chronic lymphocytic 61 CoAxia 61 metaglidasen 61 Second Pivotal Phase 61 MoxDuo TM IR 61 alvimopan 61 eosinophilic asthma 61 marketed pegylated interferons 61 CHARISMA trial 61 faropenem 61 afatinib 61 L BLP# 61 EDEMA4 61 AERx ® 61 GORE TAG Device 61 evaluating satraplatin 61 Phenoptin 61 ASPIRE HIGHER 61 muraglitazar 61 adjuvant GIST 61 ONTAK 61 ARB telmisartan 61 TAXUS V 61 torcetrapib atorvastatin 61 please visit www.advaxis.com 61 Panzem R 61 Zenvia ™ 61 sunitinib Sutent 61 docetaxel Taxotere ® 61 SWOG 61 PROPEL trial 61 Onconase 61 COPERNICUS 61 ABSORB clinical 61 ZoMaxx 61 safety tolerability pharmacokinetic 61 CRLX# 61 investigational protease inhibitor 61 Canvaxin TM 61 INTERCEPT platelets 61 TAXUS VI 61 MoxDuo IR 61 DAPT 61 Multimeric 61 vaginally administered lidocaine 61 antitumor effect 61 metreleptin 61 Board DSMB 61 ICON7 61 malignant mesothelioma Alfacell 61 GRNVAC1 61 cediranib 61 Cimzia TM 61 ReN# 61 unblinding 61 XmAb# 61 PERSEUS clinical program 61 Angiolix 61 p# biomarker 61 Edoxaban 61 Tyrima 61 BrachySil ™ 61 AeroLEF TM 61 Zensana TM 61 oral methylnaltrexone 61 Phase III ThermoDox 61 avosentan 61 Oral Calcitonin 61 ascending dose 61 Urocortin 2 61 Daclizumab 61 TELINTRA 61 pharmacogenomic translational research 60 Initiates Enrollment 60 herpetic keratitis 60 OHR/AVR# 60 Dyloject TM 60 OMAPRO ™ 60 Recurrent Glioblastoma 60 rhThrombin 60 prospective randomized multicenter 60 REVIVE TA 60 ixabepilone 60 dose escalation trial 60 Phase III 60 PIX# [002] 60 antiviral efficacy 60 Quinamed 60 HCV NS5B polymerase 60 GRNCM1 60 Zoraxel 60 bolus dose 60 BrachySil 60 multicenter dose escalation 60 initiated Phase Ib 60 RECORD1 60 lead Aganocide compound 60 CTAP# Capsules 60 analgesic efficacy 60 selective androgen receptor modulator 60 Nasdaq PGNX today 60 rNAPc2 60 endothelin antagonists 60 recurrent glioblastoma multiforme 60 Thiarabine 60 farletuzumab 60 ACCLAIM COPD 60 oral antidiabetic medication 60 acetonide FA 60 dose escalation clinical 60 preclinical pharmacokinetic 60 R sorafenib tablets 60 Phase III Pivotal 60 PROTECT AF 60 ZEGERID Capsules 60 Vilazodone 60 Xcellerated T Cells 60 Phase 2a 60 DIRECT Trial 60 GLP1 agonist 60 Acute Decompensated Heart Failure 60 HQK 60 VICTOR E1 60 Phase III ADT 60 Phase IIIB IV 60 AzaSite Plus 60 randomized controlled clinical trials 60 casopitant 60 Zybrestat 60 CTA# Injection 60 multicenter clinical trials 60 Nasdaq ONXX today 60 Phase 2b clinical trials 60 designated HVTN 60 COU AA 60 oral talactoferrin 60 Vascugel ® 60 IIa trials 60 QTinno 60 trivalent influenza vaccine 60 LB# [003] 60 AAG geldanamycin analog 60 vemurafenib 60 paclitaxel eluting stents 60 receptor tyrosine kinase inhibitor 60 next generation URAT1 60 Cleviprex TM clevidipine 60 rotary VAD 60 C#G 60 EMPOWER Study 60 prasugrel Effient 60 iroxanadine 60 fostamatinib 60 Medullary Thyroid Cancer 60 aldehyde dehydrogenase ALDH2 deficiency 60 Tekamlo 60 Corus CAD 60 Phase III TRIST 60 GENASIS clinical 60 Phase IIb 60 ACRIN 60 Virulizin ® 60 R lenalidomide 60 retinal vein occlusion induced 60 G#DT 60 Targretin capsules 60 IMPACT IMmunotherapy 60 APTIMA HPV assay 60 budesonide MMX 60 icatibant 60 SPARLON 60 CCX# 60 Matrix Phase 2b 60 arzoxifene 60 HuMax CD# 60 pradefovir 60 AIR CF2 60 BLA submission 60 nonclinical studies 60 Phase 1b dose escalation 60 masked placebo controlled 60 BENICAR HCT 60 statistically significant efficacy 60 Archexin 60 rindopepimut 60 Mg Usa 60 crizotinib PF # 60 Corlux 60 tezampanel NGX# 60 Rosuvastatin 60 INTEGRILIN R eptifibatide Injection 60 Dasatinib 60 PROSTVAC VF 60 GLYX 60 systemically administered 60 Dapagliflozin 60 Rasilez Tekturna 60 Phase IIa 60 GOUT 60 NCCTG 60 TO AVOID PREGNANCY WHILE 60 HDL Selective Delipidation 60 oxymorphone ER 60 indiplon capsules 60 GATTEX ® 60 eliglustat tartrate 60 TYGACIL 60 noninferiority 60 FOSRENOL ® 60 Screening Trial DMIST 60 RezularTM 60 Aplidin 60 Nuvion 60 alpha#beta# integrin 60 EOquin TM phase 60 Severe Sepsis 60 MICARDIS ® 60 Fx #A 60 THR beta agonist 60 PRoFESS 60 Initiates Phase II 60 Zenvia Phase III 60 PRECiSE 60 ACUITY trial 60 EGS# 60 trial evaluating PRX# 60 biostatistical analysis 60 fenofibric acid 60 isavuconazole 60 sitaxsentan 60 Vaxfectin TM 60 HORIZONS AMI trial 60 CHARM Added 60 Anturol 60 pharmacokinetic PK profile 60 aplindore 60 Fodosine 60 CytoFabTM 60 BR.# 60 Aeolus Pharmaceuticals Announces 60 Trastuzumab DM1 60 brivanib 60 oral FTY# 60 LymphoStat B TM 60 TransVax ™ 60 aflibercept 60 pharmacodynamic parameters 60 UVIDEM 60 tesmilifene 60 controlled multicenter Phase 60 atacicept 60 RIGScan CR 60 ORENCIA ® 60 ENDEAVOR clinical 60 rALLy 60 HepaMate 60 dose dose escalation 60 CD# CEA 60 relapsed ALL 60 HuMax CD4 60 Viramidine 60 ATTRACT 60 Perforomist ™ Inhalation Solution 60 regorafenib 60 Phase Ib IIa clinical 60 favorable pharmacokinetic profile 60 PREOS R 60 senicapoc 60 Committee IDMC 60 Digital Mammographic Imaging 60 CERVARIX 60 optimal dosing 60 Tavocept 60 OraTest R 60 HepeX B 60 Coronary CTA 60 PHX# 60 GENASIS trial 60 Randomized Phase II 60 safinamide 60 confirmatory Phase 3 60 Pivotal Trial 60 Safinamide 60 CLARITY study 60 Anacetrapib 60 ARIKACE ™ 60 lorvotuzumab mertansine 60 sapacitabine CYC# 60 BioNumerik 60 evaluating Nexavar 60 Surfaxin LS 60 CONQUER OB 60 kidney urologic 60 Cinquil 60 INSPIRE Trial Phase III 60 multicentre 60 viral kinetics 60 Dural Sealant 60 RGB # 60 Epanova 60 Vectibix monotherapy 60 CYT# potent vascular disrupting 60 RTP #i 60 relapsed MCL 60 T Pred 60 heterozygous FH 60 ELND# 60 Aurexis 60 glycoprotein IIb IIIa inhibitor 60 RIO Lipids 60 opioid naive 60 LCP AtorFen 60 low dose cytarabine 60 CCR9 antagonist 60 Fabry Disease 60 XP# XP# 60 pertuzumab 60 NVA# 60 DAVANAT 60 rhFVIIa 60 vitro dissolution 60 Screening Trial 60 Fondaparinux 60 Tekturna HCT 60 CDP# 60 cardio renal 60 Phase IIa trial 60 TEC #OL 60 weekly subcutaneous injections 60 HFA MDI 60 TREDAPTIVE 60 ONGLYZA ™ 60 Specifid 60 hyperphenylalaninemia HPA due 60 oral mTOR inhibitor 60 clevidipine 60 deCODE AF TM 60 PDE# inhibitors 60 Motesanib 60 CYT# QbG# 60 ASTEROID 60 Pazopanib 60 prospective observational cohort 60 BioVant 60 systemic immunosuppressive drugs 60 motesanib 60 Fibrin Pad 60 erlotinib Tarceva ® 60 telomerase inhibitor drug 60 TORISEL TM